Published in Cancer Lett on February 13, 2010
Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer (2010) 1.78
Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. Cell Death Differ (2013) 1.42
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 1.39
Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets (2012) 1.33
Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs (2010) 1.32
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther (2010) 1.28
Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death Dis (2010) 1.23
Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy. Oncogene (2015) 1.11
Selective and potent proteomimetic inhibitors of intracellular protein-protein interactions. Angew Chem Int Ed Engl (2015) 0.92
Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors. Commun Integr Biol (2012) 0.88
Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells. Oral Oncol (2013) 0.86
Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. PLoS One (2014) 0.84
Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cells. Oncotarget (2016) 0.83
Targeting Cell Survival Proteins for Cancer Cell Death. Pharmaceuticals (Basel) (2016) 0.81
Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Mol Oncol (2014) 0.81
The BH3 mimetic HA14-1 enhances 5-fluorouracil-induced autophagy and type II cell death in oesophageal cancer cells. Br J Cancer (2012) 0.80
Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis. Oncotarget (2016) 0.77
Selective and Potent Proteomimetic Inhibitors of Intracellular Protein-Protein Interactions. Angew Chem Weinheim Bergstr Ger (2015) 0.77
Dual CDK4/6 Inhibition by PD-0332991 induces apoptosis and senescence in esophageal squamous cell carcinoma cells. Br J Pharmacol (2017) 0.75
Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science (2003) 18.34
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project. Science (2010) 9.78
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med (2013) 5.38
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
A cis-regulatory map of the Drosophila genome. Nature (2011) 4.80
Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell (2007) 4.43
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
Sir2 blocks extreme life-span extension. Cell (2005) 4.25
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res (2005) 4.00
Genetic control of individual differences in gene-specific methylation in human brain. Am J Hum Genet (2010) 3.91
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
Classification of human genomic regions based on experimentally determined binding sites of more than 100 transcription-related factors. Genome Biol (2012) 3.61
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res (2008) 3.59
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 3.48
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer (2007) 3.28
Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med (2015) 3.25
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood (2005) 3.24
Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J Immunol (2004) 3.23
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2003) 3.18
Model of nonalcoholic steatohepatitis. Am J Clin Nutr (2004) 3.13
Life span extension by calorie restriction depends on Rim15 and transcription factors downstream of Ras/PKA, Tor, and Sch9. PLoS Genet (2007) 3.07
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Deep sequencing of the Camellia sinensis transcriptome revealed candidate genes for major metabolic pathways of tea-specific compounds. BMC Genomics (2011) 2.84
Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med (2011) 2.83
CTCF is conserved from Drosophila to humans and confers enhancer blocking of the Fab-8 insulator. EMBO Rep (2005) 2.80
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer (2006) 2.77
Modeling gene expression using chromatin features in various cellular contexts. Genome Biol (2012) 2.76
Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol (2007) 2.75
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood (2003) 2.75
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res (2010) 2.69
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol (2008) 2.54
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol (2003) 2.41
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov (2011) 2.38
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer (2004) 2.31
Full-Length Genome Sequence of Porcine Deltacoronavirus Strain USA/IA/2014/8734. Genome Announc (2014) 2.30
Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res (2009) 2.28
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
An analysis of the indications for cesarean section in a teaching hospital in China. Eur J Obstet Gynecol Reprod Biol (2013) 2.26
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res (2006) 2.23
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood (2005) 2.21
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res (2009) 2.19
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood (2009) 2.15
Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet (2011) 2.13
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood (2003) 2.06
Dock180 and ELMO1 proteins cooperate to promote evolutionarily conserved Rac-dependent cell migration. J Biol Chem (2003) 2.04
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol (2010) 2.02
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02
Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst (2012) 2.00
Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood (2006) 1.97
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer (2007) 1.95
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol (2005) 1.93
Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol (2010) 1.92
Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One (2010) 1.92
High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med (2014) 1.91
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer (2003) 1.90
MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS One (2011) 1.90
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol (2009) 1.88
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood (2003) 1.87
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol (2007) 1.85
Zebrafish miR-1 and miR-133 shape muscle gene expression and regulate sarcomeric actin organization. Genes Dev (2009) 1.84
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol (2009) 1.83
Plating osteosynthesis of mid-distal humeral shaft fractures: minimally invasive versus conventional open reduction technique. Int Orthop (2009) 1.82
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood (2009) 1.82
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer (2008) 1.80
Quality of Research Design Moderates Effects of Grade Retention on Achievement: A Meta-analytic, Multi-level Analysis. Educ Eval Policy Anal (2009) 1.78
Biotic and human vulnerability to projected changes in ocean biogeochemistry over the 21st century. PLoS Biol (2013) 1.78
Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer (2008) 1.77
MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res (2011) 1.77
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer (2004) 1.75
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood (2006) 1.73
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood (2003) 1.72
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol (2013) 1.70
RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo. Breast Cancer Res Treat (2009) 1.68
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res (2004) 1.68
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica (2010) 1.65
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood (2013) 1.64
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer (2010) 1.64
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol (2009) 1.64
Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol Cell (2012) 1.63
Highly flexible silver nanowire electrodes for shape-memory polymer light-emitting diodes. Adv Mater (2010) 1.62
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res (2013) 1.61
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res (2005) 1.61
Role of angiogenesis in chronic lymphocytic leukemia. Cancer (2006) 1.60
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol (2006) 1.60
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res (2013) 1.59
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood (2011) 1.58